Northern Trust Corp Adaptimmune Therapeutics PLC Transaction History
Northern Trust Corp
- $761 Billion
- Q3 2025
A detailed history of Northern Trust Corp transactions in Adaptimmune Therapeutics PLC stock. As of the latest transaction made, Northern Trust Corp holds 48,584 shares of ADAP stock, worth $1,457. This represents 0.0% of its overall portfolio holdings.
Number of Shares
48,584
Previous 51,333
5.36%
Holding current value
$1,457
Previous $12,000
50.0%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding ADAP
# of Institutions
60Shares Held
41.9MCall Options Held
139KPut Options Held
144K-
Long Focus Capital Management, LLC San Juan, PR18.6MShares$557,3340.1% of portfolio
-
Ubs Group Ag6.67MShares$200,0200.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny4.05MShares$121,6220.0% of portfolio
-
Morgan Stanley New York, NY3.67MShares$109,9810.0% of portfolio
-
Jane Street Group, LLC New York, NY2.81MShares$84,1600.0% of portfolio
About Adaptimmune Therapeutics PLC
- Ticker ADAP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 163,370,000
- Market Cap $4.9M
- Description
- Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...